Survival in women with ovarian cancer before and after the introduction of adjuvant paclitaxel; a 25-year, single institution review.
dc.contributor.author | Shireen, R | |
dc.contributor.author | Brennan, D | |
dc.contributor.author | Flannelly, G | |
dc.contributor.author | Fennelly, D | |
dc.contributor.author | Lenehan, P | |
dc.contributor.author | Foley, M | |
dc.date.accessioned | 2012-07-11T14:57:23Z | |
dc.date.available | 2012-07-11T14:57:23Z | |
dc.date.issued | 2012-02 | |
dc.identifier.citation | Survival in women with ovarian cancer before and after the introduction of adjuvant paclitaxel; a 25-year, single institution review. 2012, 105 (2):47-50 Ir Med J | en_GB |
dc.identifier.issn | 0332-3102 | |
dc.identifier.pmid | 22455239 | |
dc.identifier.uri | http://hdl.handle.net/10147/233251 | |
dc.description.abstract | Adjuvant chemotherapy regime for ovarian cancer patients remains to be a contentious issue. The aim of this study was to compare the overall and progression-free survival of women with ovarian cancer before and after introduction of paclitaxel in our unit in 1992. A sample of 112 women who received adjuvant therapy following surgery for ovarian cancer was collected, 68 (61%) received platinum+alkylating agent before 1992 and later 44 (39%) received platinum+paclitaxel. Five-year survival was same in both treatment groups when there was no macroscopic disease after surgery (78% versus 70%) and when residual disease was <2 cm (50% versus 40%). Survival was greater in women with residual disease >2 cm in the platinum+paclitaxel group (50% versus 24%), (p = 0.04). However, progression-free survival was similar in both groups irrespective of stage or residual volume of disease. Therefore consideration to selective use of paclitaxel could reduce patient morbidity and costs significantly. | |
dc.language.iso | en | en |
dc.publisher | Irish Medical Journal (IMJ) | en_GB |
dc.relation.url | http://www.ncbi.nlm.nih.gov/pubmed?term=Survival%20in%20Women%20with%20Ovarian%20Cancer%20Before%20and%20After%20the%20Introduction%20of%20Adjuvant%20Paclitaxel%3B%20A%2025-Year%2C%20Single%20Institution%20Review | en_GB |
dc.rights | Archived with thanks to Irish medical journal | en_GB |
dc.subject.mesh | Adenocarcinoma | |
dc.subject.mesh | Adenocarcinoma, Mucinous | |
dc.subject.mesh | Chemotherapy, Adjuvant | |
dc.subject.mesh | Cystadenocarcinoma, Serous | |
dc.subject.mesh | Female | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Neoplasm, Residual | |
dc.subject.mesh | Ovarian Neoplasms | |
dc.subject.mesh | Paclitaxel | |
dc.title | Survival in women with ovarian cancer before and after the introduction of adjuvant paclitaxel; a 25-year, single institution review. | en_GB |
dc.type | Article | en |
dc.contributor.department | Department of Obstetrics, National Maternity Hospital, Holles St., Dublin 2. | en_GB |
dc.identifier.journal | Irish medical journal | en_GB |
dc.description.province | Leinster | en |
refterms.dateFOA | 2018-08-22T18:00:22Z | |
html.description.abstract | Adjuvant chemotherapy regime for ovarian cancer patients remains to be a contentious issue. The aim of this study was to compare the overall and progression-free survival of women with ovarian cancer before and after introduction of paclitaxel in our unit in 1992. A sample of 112 women who received adjuvant therapy following surgery for ovarian cancer was collected, 68 (61%) received platinum+alkylating agent before 1992 and later 44 (39%) received platinum+paclitaxel. Five-year survival was same in both treatment groups when there was no macroscopic disease after surgery (78% versus 70%) and when residual disease was <2 cm (50% versus 40%). Survival was greater in women with residual disease >2 cm in the platinum+paclitaxel group (50% versus 24%), (p = 0.04). However, progression-free survival was similar in both groups irrespective of stage or residual volume of disease. Therefore consideration to selective use of paclitaxel could reduce patient morbidity and costs significantly. |